Taysha Gene Therapies Inc (NASDAQ:TSHA) shares, rose in value on Wednesday, July 09, with the stock price up by 4.96% to the previous day’s close as strong demand from buyers drove the stock to $2.54.
Actively observing the price movement in the last trading, the stock closed the session at $2.42, falling within a range of $2.4405 and $2.575. The value of beta (5-year monthly) was 1.016. Referring to stock’s 52-week performance, its high was $3.31, and the low was $1.05. On the whole, TSHA has fluctuated by -10.56% over the past month.
With the market capitalization of Taysha Gene Therapies Inc currently standing at about $664.28 million, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-May-15.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that TSHA’s technical picture suggests that short-term indicators denote the stock is a 50% Buy on average. However, medium-term indicators have put the stock in the category of 100% Buy while long-term indicators on average have been pointing out that it is a 100% Buy.
The stock’s technical analysis shows that the price of TSHA currently trading nearly 2.56% and 1.97% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 53.68, while the 7-day volatility ratio is showing 6.07% which for the 30-day chart, stands at 7.00%. Furthermore, Taysha Gene Therapies Inc (TSHA)’s beta value is 0.95.
A comparison of Taysha Gene Therapies Inc (TSHA) with its peers suggests the former has fared considerably weaker in the market. TSHA showed an intraday change of 4.96% in last session, and over the past year, it grew by 46.82%%.
Data on historical trading for Taysha Gene Therapies Inc (NASDAQ:TSHA) indicates that the trading volumes over the past 10 days have averaged 2.08 and over the past 3 months, they’ve averaged 3.69 million. According to company’s latest data on outstanding shares, there are 261.53 million shares outstanding.
Nearly 18.37% of Taysha Gene Therapies Inc’s shares belong to company insiders and institutional investors own 66.25% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 33.27 million shares as on 2025-06-13, resulting in a short ratio of 6.71. According to the data, the short interest in Taysha Gene Therapies Inc (TSHA) stood at 1429.00 of shares outstanding as of 2025-06-13; the number of short shares registered in 2025-05-15 reached 26.24 million. The stock has risen by 22.71% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the TSHA stock heading into the next quarter.
